Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This study is being done to see if combining HEPZATO KIT with nivolumab and relatlimab (Opdualag) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.